In accordance with the Office of Management and Budget (OMB) guidelines for economic analysis, we use a real social discount rate of 3 percent in the analysis. The social discount rate is assumed to have a triangular probability distribution with a lower bound of 1 percent and an upper bound of 7 percent in the sensitivity analysis.
Table 15: Social EPV Model Parameters and Assumptions (Point Estimates)
Model Parameter/Assumption | ABOM | ABSSSI | CABP | CIAI | CUTI | HABP/VABP |
---|---|---|---|---|---|---|
Real Annual Social Rate of Discount
|
3% | |||||
% of Patients Not Responding to Existing Drugs | 20% | |||||
% Increase in Duration in Patients Not Responding to Existing Drugs | 50% | |||||
Loss in Quality of Life, Acute | 0.11 | 0.36 | 0.15 | 0.5 | 0.27 | 0.17 |
Duration (days) | 10 | 6 | 4 | 10 | 4 | 8.5 |
Loss in Quality of Life, Convalescence | 0.04 | 0.36 | 0.1 | 0.15 | N/A | N/A |
Duration (days) | 20 | 18 | 5 | 12 | N/A | N/A |
Lost QALYs per illness | 0.0049 | 0.0239 | 0.0038 | 0.0023 | 0.0030 | 0.0040 |
Total Number of Cases per Year (unadjusted for population growth) | 13,200,000 | 726,000 | 1,170,000 | 72,000 | 1,083,000 | 272,600 |
Mortality Parameters | ||||||
Deaths | 0 | 1,923 | 51,683 | 14,554 | 36,900 | 81,779 |
Lost QALYs for Patients that Die | 0 | 26,167 | 572,741 | 243,987 | 319,913 | 1,848,212 |
VSL per Patient | N/A | $5,623,708 | $5,301,924 | $5,585,504 | $4,953,688 | $4,770,000 |
Morbidity Parameters | ||||||
Number of Patients that Survive | 13,200,000 | 724,397 | 1,118,000 | 57,489 | 1,045,986 | 190,818 |
Lost QALYs for Patients that Survive | 65,248 | 17,336 | 4,295 | 1,632 | 2,432 | 756 |
WTP (VSLY*Lost QALYs) per patient | $1,124 | $8,749 | $1,113 | $12,717 | $758 | $1,149 |
N/A = Not applicable
QALY = Quality-adjusted-life-year
VSL = Value of a statistical life
VSLY = Value of a statistical life year
WTP = Willingness-to-pay
The figures in the table are rounded for presentation purposes.
View full report

"rpt_antibacterials.pdf" (pdf, 1.43Mb)
Note: Documents in PDF format require the Adobe Acrobat Reader®. If you experience problems with PDF documents, please download the latest version of the Reader®